Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. Repligen’s corporate headquarters are located in Waltham, MA, USA; we have an additional manufacturing facility in Lund, Sweden.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)+41%
Repligen was founded in 1981 and is headquartered in Waltham, US

Repligen Office Locations

Repligen has offices in Waltham and Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars Väg

Repligen Data and Metrics

Repligen Financial Metrics

Repligen's revenue was reported to be $104.5 m in FY, 2016 which is a 25% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

104.5 m

Revenue growth (FY, 2015 - FY, 2016), %

25%

Net income (FY, 2016)

11.7 m

EBIT (FY, 2016)

16 m

Market capitalization (24-May-2017)

1.3 b

Closing share price (24-May-2017)

38.6

Cash (31-Dec-2016)

122.2 m
Repligen's current market capitalization is $1.3 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.2 m63.5 m83.5 m104.5 m

Revenue growth, %

(7%)31%25%

Gross profit

45.7 m35.5 m48.3 m

Gross profit Margin, %

67%56%58%

Operating expense total

22.8 m24.8 m34.5 m88.6 m

EBIT

22.9 m10.7 m13.8 m16 m

EBIT margin, %

34%17%16%15%

Interest expense

27.8 k50 k32 k3.8 m

Pre tax profit

(1.6 m)11.1 m13.4 m11.7 m

Income tax expense

15.7 k3 m4.1 m11 k

Net Income

16.1 m8.2 m9.3 m11.7 m
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.8 m35.4 m54.1 m122.2 m

Accounts Receivable

Inventories

1.2 m2.1 m2.1 m1.6 m

Current Assets

86.4 m80.9 m103.3 m184.2 m

PP&E

12.5 m14.5 m13.8 m15 m

Goodwill

994 k14.2 m14.3 m59.5 m

Total Assets

118.6 m128.3 m146.2 m288.9 m

Accounts Payable

1.7 m3.9 m6.7 m5.1 m

Current Liabilities

11.3 m10.7 m18.8 m21.1 m

Additional Paid-in Capital

190.6 m198.1 m202.5 m242 m

Retained Earnings

(89.1 m)(80.9 m)(71.5 m)(59.9 m)

Total Equity

103.9 m111.7 m122.7 m168.8 m

Financial Leverage

1.1 x1.1 x1.2 x1.7 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.6 m)8.2 m9.3 m11.7 m

Depreciation and Amortization

1.3 m4 m4.6 m5.3 m

Accounts Receivable

3.6 m(1.6 m)(3.7 m)(3.2 m)

Inventories

(870.3 k)(860.1 k)(6.1 m)(6.2 m)

Accounts Payable

247.2 k2.3 m3 m(1.8 m)

Cash From Operating Activities

2.3 m18.4 m15.1 m7.5 m

Purchases of PP&E

(575.5 k)(5.6 m)(2.6 m)(4.3 m)

Cash From Investing Activities

(5 m)(19.8 m)4.8 m(49.2 m)

Cash From Financing Activities

(330.8 k)1.7 m767 k112.1 m

Income Taxes Paid

2.5 m4.9 m4 m
Y, 2016

Financial Leverage

1.7 x

Repligen Market Value History

Repligen Online and Social Media Presence

Repligen Company Life and Culture

You may also be interested in